From Disease Susceptibility to Prognosis in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension: A Systematic Review
Journal of Cardiovascular Development and Disease · 20.11.2026 · 13 (11) · 612
DOI: 10.3390/jcdd13110612 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Cardiovascular Development and Disease, online erschienen am 20.11.2026. Verfasst von Mislav Radić und 7 weiteren Autor:innen. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Systemic lupus erythematosus-associated pulmonary arterial hypertension (SLE-PAH) is a severe complication requiring early recognition and risk stratification. However, factors associated with prevalent disease, non-invasive detection, incident PAH, and prognosis after diagnosis are frequently conflated.
Methods
PubMed, Web of Science, Scopus, and the Cochrane Library were initially searched through 23 September 2026, and searches of all four databases were updated on 1 November 2026. Observational evidence was evaluated using a structured clinical-pathway framework and the Newcastle–Ottawa Scale, and findings were synthesized narratively because of clinical and methodological heterogeneity and potentially overlapping cohorts.
Results
Thirty-five studies were included in the qualitative synthesis. Serositis, interstitial lung disease, pericardial effusion, anti-U1 RNP and anti-Ro/SSA antibodies, reduced diffusing capacity, and microvascular abnormalities were mainly associated with prevalent or concomitant disease. Non-invasive detection was supported by a multimodal approach incorporating symptoms, biomarkers, pulmonary function, and echocardiography, with right heart catheterization required for PAH confirmation. Evidence on incident, catheterization-confirmed PAH prediction was limited. After diagnosis, functional class, exercise capacity, pulmonary vascular load, right-heart function, and serial risk status were recurrent prognostic indicators.
Conclusions
Evidence is more extensive for prognosis after established SLE-PAH than for incident prediction, highlighting the need for externally validated SLE-specific screening and risk-stratification tools.
Zitieren
APA
Radić, M., Bečić, T., Prižmić, P. Š., Đogaš, H., Perković, D., Hećimović, A., Fabijanić, D., & Radić, J. (2026). From Disease Susceptibility to Prognosis in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension: A Systematic Review. Journal of Cardiovascular Development and Disease, 13(11), 612. https://doi.org/10.3390/jcdd13110612
Vancouver
Radić M, Bečić T, Prižmić PŠ, Đogaš H, Perković D, Hećimović A, et al. From Disease Susceptibility to Prognosis in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension: A Systematic Review. Journal of Cardiovascular Development and Disease. 2026;13(11):612. doi:10.3390/jcdd13110612
BibTeX
@article{Radi2026,
author = {Radić, Mislav and Bečić, Tina and Prižmić, Petra Šimac and Đogaš, Hana and Perković, Dijana and Hećimović, Ana and Fabijanić, Damir and Radić, Josipa},
title = {From Disease Susceptibility to Prognosis in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension: A Systematic Review},
journal = {Journal of Cardiovascular Development and Disease},
year = {2026},
volume = {13},
number = {11},
pages = {612},
doi = {10.3390/jcdd13110612}
}
EUVIMED